Nordic Stocks: Bionor, FLSmidth, Getinge, Lundin, Novo, Vestas

The Stoxx Nordic 30 Index, the benchmark measure for the region, gained 0.7 percent to 7,323.87 at the 5:30 p.m. close in Stockholm, paring two days of losses. The gauge has advanced less than 0.1 percent this week.

The OMX Stockholm 30 Index rose 0.5 percent and the Copenhagen 20 Index added 2.2 percent. Norway’s OBX Index fell 0.8 percent, while the OMX Helsinki 25 Index lost 0.3 percent.

The following shares were among the most active in Nordic markets today. Symbols are in parentheses.

Bionor Pharma ASA (BIONOR NO) rose 17 percent to 1.92 kroner, the biggest jump in two weeks. The Norwegian biotechnology company signed a memorandum of understanding with Axellus, which is owned by Orkla ASA, to transfer its Nutrilett trademarks to Axellus for 110 million kroner ($18.3 million).

FLSmidth & Co. A/S (FLS DC) rose for the first time in three days, gaining 1.2 percent to 525 kroner. The world’s largest maker of cement production equipment said it won a 30 million-euro ($40 million) order in Russia.

Getinge AB (GETIB SS) slipped for a second day, losing 2.3 percent to 144.10 kronor. JPMorgan Chase & Co. cut its recommendation on the shares of the world’s largest maker of surgical workstations to “underweight” from “neutral.”

Lundin Mining Corp. (LUMI SS) slid 1.8 percent to 48.30 kronor, erasing yesterday’s 0.6 percent gain. The company that mines zinc, copper and lead in Europe said it suspended its full-scale pit operations at Aguablanca in Spain because of heavy rains over the past few days.

Novo Nordisk A/S (NOVOB DC) advanced for a fourth day this week, gaining 4.3 percent to 607.5 kroner. The world’s largest maker of insulin was raised to “buy” from “hold” at Citigroup Inc.

Vestas Wind Systems A/S (VWS DC), the world’s largest maker of wind turbines, rose the most in eight months, jumping 7 percent to 171 kroner. U.S. Senate negotiators approved the extension of grants to wind and solar power companies by one year. The grants, which still need to be passed by the full Senate, pay developers for almost one-third of their projects’ value.

To contact the reporter on this story: {Christian Wienberg} in Copenhagen at cwienberg@bloomberg.net

To contact the editor responsible for this story: David Merritt at dmerritt1@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.